Folio · SPXSet Report · Digest
v0.7.0 STABLE · 2026-11-11 · r4

2026-W46 · Nov 9–Nov 15 · Company · Profile · published

Index >>> Company >>> Profile

Insulet Corporation (PODD) — XLV Health Care · S&P 500 Profile |Insulet公司介紹

health-careS&P500xlv
SPXSet Studio
IN-HOUSE RESEARCH · 站內獨立研究

Insulet Corporation (PODD) — Business, History & S&P 500 Profile | Insulet公司介紹

Insulet Corporation company profile · business segments · history · financial snapshot · S&P 500 rank #488 · Insulet公司業務歷史財務與標普500地位

中文版 ↓

PROFILE
Market data as of Nov 5, 2026
Financials: FY2025
MARKET CAP
$11.16B
Nov 5, 2026
S&P 500 WEIGHT
0.02%
Rank #488 · Nov 5, 2026
SECTOR RANK
#59
Health Care · Nov 5, 2026
S&P 500 RANK
#488
0.02% · Nov 5, 2026

SNAPSHOT

TickerPODD
CompanyInsulet Corporation
GICS sector / industryHealth Care (XLV) / Health Care Equipment
S&P 500 rank (by weight)#488 · 0.02% (Nov 5, 2026)
Sector rank#59 of 60 in Health Care (Nov 5, 2026)
HeadquartersActon, Massachusetts
Founded2000
CEOAshley McEvoy (President and Chief Executive Officer)
Employees~5,400 (as of December 31, 2025)
Market cap$11.16B (Nov 5, 2026)
SEC filingsEDGAR — CIK 1145197

WHAT IT DOES

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, built around one product platform: Omnipod, a tubeless, disposable insulin pump worn directly on the body. Its Omnipod 5 system automates insulin delivery using readings from a continuous glucose monitor, serving people with type 1 and type 2 diabetes, mainly in the United States and increasingly in international markets.

Its one-line model: sell the wearable Pod as a recurring consumable through pharmacy and distributor channels, so revenue repeats with every Pod change rather than depending on a one-off device sale. Fiscal 2025 revenue was $2,708.1M, of which Omnipod products were $2,674.0M.

BUSINESS SEGMENTS

Single reportable segment — Omnipod platformInsulet operates in one reportable segment. Fiscal 2025 revenue by product: Omnipod products $2,674.0M and Drug Delivery $34.1M; by customer location, United States $1,953.9M and International $754.3M.
The fiscal 2025 Form 10-K (Note 3) states the company operates in one reportable segment; the product and geographic splits above are the 10-K disaggregated revenue disclosures, not separate segments.

HISTORY

YearMilestone
2000Insulet is founded in Massachusetts to develop a tubeless, wearable insulin delivery system — the Omnipod platform.
2005The first Omnipod insulin management system reaches the market, replacing tubed pumps with a disposable wearable Pod.
2007Insulet completes its initial public offering and lists on Nasdaq.
2022The FDA clears Omnipod 5, the company's automated insulin delivery system integrating continuous glucose monitoring.
2025Ashley McEvoy becomes President and CEO in April 2025, succeeding James Hollingshead; revenue reaches $2,708.1M in fiscal 2025.

COMPETITIVE POSITION

  • Category creation: Insulet pioneered tubeless patch-pump delivery, a form factor tubed-pump makers cannot copy without redesigning their installed base.
  • Recurring consumable economics: Pods are replaced every few days, producing repeat revenue and high switching friction once a patient is trained on the system.
  • Automation and integration: Omnipod 5 pairs the Pod with continuous glucose monitors and a proprietary control algorithm, competing on outcomes and convenience.
  • Competition set: Medtronic (MiniMed tubed pumps), Tandem Diabetes Care (t:slim / Mobi) and Abbott and Dexcom on the sensing side; Insulet is the tubeless pure play among them.

FINANCIAL SNAPSHOT

Total revenue$2.71B (FY2025 revenue)
Operating income$473.8M (FY2025 operating income)
Net income$247.1M (FY2025 net income)
Diluted EPS$3.48 (FY2025 diluted EPS)
Source: Insulet Corporation fiscal 2025 Form 10-K (year ended December 31, 2025; filed February 18, 2026). Exact figures: total revenue $2,708.1M; operating income $473.8M; net income $247.1M; diluted EPS $3.48. Employee count is the 10-K human-capital figure (~5,400 full-time employees as of December 31, 2025, ~60% in the United States). Fiscal 2025 results include a $123.9M loss on extinguishment of debt and $9.3M of CEO and CFO transition costs disclosed in the 10-K non-GAAP reconciliation.

KEY RISKS

  • Single-platform concentration: essentially all revenue depends on the Omnipod platform, so a product, safety or supply problem hits the whole company.
  • Customer concentration: three distributors each accounted for 25% or more of fiscal 2025 revenue (27%, 26% and 25% per the 10-K).
  • Leadership transition: the CEO and CFO both changed in 2025, and the 10-K flags integration and continuity of the new management team as a risk.
  • Reimbursement and pricing: growth depends on pharmacy-channel coverage and payer decisions in the U.S. and abroad, and on keeping pace with larger rivals' automated systems.

WHY IT MATTERS FOR THE S&P 500

Insulet is a small-weight Health Care constituent: rank #488 by weight at 0.02% as of Nov 5, 2026, and #59 in Health Care. It matters as the index's pure-play exposure to automated insulin delivery — a device category still penetrating the large type 2 diabetes population, where adoption, not market size, is the constraint.

SOURCES & METHODOLOGY

Financials, segments, headquartersInsulet Corporation fiscal 2025 Form 10-K via SEC EDGAR (see Financial Snapshot note); headquarters, CEO and history via the Form 10-K and Wikipedia company profile
Index weight & ranksSlickcharts S&P 500 weights, fetched Nov 5, 2026; sector membership per Wikipedia List of S&P 500 companies (GICS)
Market cap$11.16B (Slickcharts, Nov 5, 2026)
LogoSPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics.
ChartSPXSet chart library, monthly bars, compiled from Yahoo public information.

Price Chart — 10-Year Monthly Candles

PODD

Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com

FINANCIALS

繁體中文版

公司快照

股票代號PODD
公司Insulet Corporation(Insulet)
GICS 板塊/行業健康護理(XLV)/醫療設備
標普500排名(按權重)#488 · 0.02%(Nov 5, 2026)
板塊內排名健康護理板塊 #59(共 60 家)(Nov 5, 2026)
總部美國麻薩諸塞州阿克頓
成立2000年
執行長Ashley McEvoy(總裁兼執行長)
員工約5,400人(截至2025年12月31日)
市值$11.16B(Nov 5, 2026)
SEC 申報EDGAR — CIK 1145197

業務概覽

Insulet Corporation 是總部位於麻薩諸塞州阿克頓的醫療設備公司,業務圍繞單一產品平台:Omnipod — 直接佩戴在身上的無管一次性胰島素泵。其 Omnipod 5 系統利用連續血糖監測讀數自動遞送胰島素,服務第一型及第二型糖尿病患者,主要市場在美國,國際市場佔比正提升。

其一句話商業模式是:透過藥房與分銷渠道把可穿戴 Pod 作為經常性消耗品銷售,收入隨每次更換 Pod 重複產生,而非依賴一次性設備銷售。2025 財年收入為 27.081 億美元,其中 Omnipod 產品佔 26.740 億美元。

業務板塊

單一可呈報板塊 — Omnipod 平台Insulet 以單一可呈報板塊營運。2025 財年收入按產品劃分:Omnipod 產品 26.740 億美元、藥物遞送 3,410 萬美元;按客戶所在地劃分:美國 19.539 億美元、國際 7.543 億美元。
2025 財年 Form 10-K(附註 3)述明公司以單一可呈報板塊營運;上列產品與地區劃分是 10-K 的收入細分披露,並非獨立板塊。

歷史

年份里程碑
2000Insulet 在麻薩諸塞州成立,開發無管、可穿戴的胰島素遞送系統 — Omnipod 平台。
2005首個 Omnipod 胰島素管理系統推出市場,以一次性可穿戴 Pod 取代有管泵。
2007Insulet 完成首次公開招股,在納斯達克上市。
2022美國食品藥物管理局核准 Omnipod 5 — 結合連續血糖監測的自動胰島素遞送系統。
2025Ashley McEvoy 於 2025 年 4 月出任總裁兼執行長,接替 James Hollingshead;2025 財年收入達 27.081 億美元。

競爭地位

  • 開創品類:Insulet 首創無管貼片式泵遞送,有管泵廠商若要複製,須重新設計其既有產品基礎。
  • 經常性消耗品經濟:Pod 每隔數天更換,帶來重複收入;患者一旦熟習系統,轉換誘因很低。
  • 自動化與整合:Omnipod 5 把 Pod 與連續血糖監測及自有控制演算法結合,以療效與便利競爭。
  • 競爭對手:Medtronic(MiniMed 有管泵)、Tandem Diabetes Care(t:slim / Mobi),以及感測端的 Abbott 與 Dexcom;Insulet 是其中專注無管方案的一家。

財務快照

總收入27.08 億美元(2025 財年收入)
營業利潤4.74 億美元(2025 財年營業利潤)
淨利潤2.47 億美元(2025 財年淨利潤)
稀釋 EPS3.48 美元(2025 財年稀釋 EPS)
來源:Insulet Corporation 2025 財年 Form 10-K(截至2025年12月31日止年度;2026年2月18日申報)。確實數字:總收入 27.081 億美元;營業利潤 4.738 億美元;淨利潤 2.471 億美元;稀釋 EPS 3.48 美元。員工數字為 10-K 人力資本披露(截至2025年12月31日約 5,400 名全職員工,約 60% 位於美國)。2025 財年業績包括 10-K 非 GAAP 調節表披露的 1.239 億美元債務清償損失及 930 萬美元執行長與財務長交接成本。

主要風險

  • 單一平台集中:收入幾乎全部依賴 Omnipod 平台,產品、安全或供應一旦出問題,將衝擊全公司。
  • 客戶集中:2025 財年三家分銷商各佔收入 25% 或以上(據 10-K 分別為 27%、26% 及 25%)。
  • 管理層交接:執行長與財務長均於 2025 年更換,10-K 把新管理團隊的磨合與延續列為風險。
  • 報銷與定價:增長依賴美國及海外藥房渠道的覆蓋與付款方決定,也取決於能否跟上較大型對手的自動化系統。

對標普500的重要性

Insulet 是權重較小的健康護理成分股:截至 2026 年 11 月 5 日按權重排名第 488 位,權重 0.02%,在健康護理板塊排第 59 位。其重要性在於它是標普 500 中專注自動胰島素遞送的代表 — 該設備品類正滲透龐大的第二型糖尿病群體,限制因素是採用率而非市場規模。

來源與方法

財務、板塊、總部Insulet Corporation 2025 財年 Form 10-K,經 SEC EDGAR(見財務快照附註);總部、執行長與歷史經 Form 10-K 及維基百科公司簡介核對
指數權重與排名Slickcharts 標普 500 權重,Nov 5, 2026 抓取;板塊歸屬按維基百科標普 500 成分股名單(GICS)
市值$11.16B(Slickcharts,Nov 5, 2026)
LogoSPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。
股價圖SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。

10年股價K線圖(月K)

PODD

來源:Yahoo Finance 月線(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份)· SPXSet.com

財報

SPXSet Studio

SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。

SPXSet · Company Library · PODD
Data as of Nov 5, 2026 · Financials FY2025 (10-K) · Market data Nov 2026
Previous · Generac Holdings Inc. (GNRC) — XLI Industrials · S&P 500 Profile |Generac公司介紹Next · Albemarle Corporation (ALB) — XLB Materials · S&P 500 Profile |雅寶公司介紹

Entered 2026-11-04 14:49 · updated 2026-11-14 23:56 · rev 6